Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication.
During 24 hours after administration of chemotherapy.
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos